18889881171
Kalkine 0
countryflagUS
Login

AAPL 177.845 3.1464% MSFT 358.75 1.1817% NVDA 99.14 2.9491% GOOGL 144.9 0.1382% GOOG 146.85 0.1842% AMZN 172.42 1.0313% META 508.16 -0.4486% AVGO 158.6 1.6471% LLY 695.065 -4.2927% TSLA 229.895 3.6217% TSM 139.08 -1.6199% V 308.57 0.0973% JPM 212.075 -2.211% UNH 558.98 1.0668% NVO 59.71 -3.0682% WMT 84.68 3.5334% LVMUY 111.0 3.9131% XOM 99.055 -1.7019% LVMHF 555.0 1.5935% MA 473.61 -1.1583%
AAPL 177.845 3.1464% MSFT 358.75 1.1817% NVDA 99.14 2.9491% GOOGL 144.9 0.1382% GOOG 146.85 0.1842% AMZN 172.42 1.0313% META 508.16 -0.4486% AVGO 158.6 1.6471% LLY 695.065 -4.2927% TSLA 229.895 3.6217% TSM 139.08 -1.6199% V 308.57 0.0973% JPM 212.075 -2.211% UNH 558.98 1.0668% NVO 59.71 -3.0682% WMT 84.68 3.5334% LVMUY 111.0 3.9131% XOM 99.055 -1.7019% LVMHF 555.0 1.5935% MA 473.61 -1.1583%

GlucoTrack Inc

Healthcare US GCTK

0.1525USD
0.0055(3.74%)

Last update at 2025-04-09T14:50:00Z

Day Range

0.140.15
LowHigh

52 Week Range

0.674.95
LowHigh

Fundamentals

  • Previous Close 0.15
  • Market Cap11.56M
  • Volume394664
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.75875M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.02000M
  • Diluted EPS TTM-2.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-31-6.5M-6M-5.5M-5M-4.5M-4M-3.5M-3M-2.5M-2M-1.5M-1M-0.5M0M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M1M2M3M4M5M6M7M8M9M10M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-312023-12-31-3M-2M-1M0M1M2M3M4M5M6M7M8M9M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-312023-12-31-7M-6.5M-6M-5.5M-5M-4.5M-4M-3.5M-3M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -4.43500M -4.06700M -2.69600M -3.51615M -6.71542M
Minority interest - - - - -
Net income -4.43800M -4.10000M -2.59800M -3.51619M -6.71542M
Selling general administrative 2.45M 1.98M 1.14M 2.04M 3.48M
Selling and marketing expenses - 0.14M 0.41M 0.03M 0.00594M
Gross profit - - - 0.21M 0.04M
Reconciled depreciation 0.02M 0.04M 0.05M 0.05M 0.06M
Ebit -4.43200M -4.04000M 3.13M 3.51M -6.53767M
Ebitda -4.40900M -3.88000M -3.08500M -3.46259M -6.47888M
Depreciation and amortization 0.02M 0.16M -6.21700M -6.96822M 0.06M
Non operating income net other - - - - -
Operating income -4.43200M -4.04000M 3.13M 3.51M 6.54M
Other operating expenses 4.43M 3.98M 3.13M 3.71M 6.58M
Interest expense 0.00300M 4.16M 0.10M 0.00004M 0.02M
Tax provision - - - - -
Interest income 0.01M 0.03M - - -
Net interest income 0.01M 0.03M 0.10M -0.00760M -0.01736M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00300M 0.03M -0.09800M 0.00004M -13.23573M
Total revenue 0.00000M 0.00000M 0.00000M 0.21M 0.04M
Total operating expenses 4.43M 3.98M 3.13M 3.71M 6.58M
Cost of revenue - - - - -
Total other income expense net -0.00300M -0.02700M -5.82800M -7.02177M -0.15946M
Discontinued operations - - - - -
Net income from continuing ops -4.43500M -4.06700M -2.69600M -3.51615M -6.71542M
Net income applicable to common shares -4.43500M -4.06700M -2.69600M -3.51600M -39.81817M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.91M 2.44M 6.26M 10.61M 1.28M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.38M 0.07M 0.04M 0.06M 0.02M
Total liab 1.71M 1.21M 1.11M 1.62M 2.69M
Total stockholder equity 3.20M 1.23M 5.16M 8.98M -1.41160M
Deferred long term liab - - - - -
Other current liab 0.67M 0.34M 0.23M 0.39M 0.60M
Common stock 0.02M 0.01M 0.01M 0.20M 0.16M
Capital stock 0.02M 0.01M 0.01M 0.20M 0.16M
Retained earnings -109.85300M -101.90100M -97.46600M -93.39900M -90.70293M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 0.02M 0.05M 0.06M 0.06M
Cash 4.49M 2.31M 6.06M 9.82M 0.42M
Cash and equivalents - - - - -
Total current liabilities 1.51M 1.01M 0.88M 1.34M 2.27M
Current deferred revenue - - - - -
Net debt -4.29600M -2.11700M -5.81200M -9.46000M -0.04102M
Short term debt - - 0.02M 0.08M 0.14M
Short long term debt - - - - -
Short long term debt total 0.20M 0.20M 0.25M 0.36M 0.38M
Other stockholder equity 112.97M 103.10M 102.61M 102.17M 89.00M
Property plant equipment - 0.04M 0.11M 0.32M 0.32M
Total current assets 4.87M 2.38M 6.11M 10.23M 0.72M
Long term investments - - - - -
Net tangible assets - 1.23M 5.16M 8.98M -1.41200M
Short term investments - - - - -
Net receivables - - 0.00000M 0.07M 0.07M
Long term debt 0.20M 0.20M 0.21M 0.20M 0.19M
Inventory - - 0.00000M 0.28M 0.18M
Accounts payable 0.84M 0.67M 0.63M 0.87M 1.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.06M 0.02M -0.00600M 0.01M 0.12M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 0.02M 0.05M 0.06M 0.24M
Deferred long term asset charges - - - - -
Non current assets total 0.04M 0.06M 0.16M 0.38M 0.56M
Capital lease obligations - 0.00000M 0.04M 0.17M 0.19M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.00500M 0.00100M -0.00100M -0.05300M -0.02343M
Change to liabilities - 0.07M -0.25700M -0.71400M -0.60000M
Total cashflows from investing activities - 0.00100M -0.00100M -0.05300M -0.02300M
Net borrowings - - - - -
Total cash from financing activities 0.00873M 0.00000M 0.00000M 13.01M 4.20M
Change to operating activities - 0.11M -0.15700M -0.24500M -0.31000M
Net income -7.09700M -4.43500M -4.06700M -2.69600M -3.51615M
Change in cash 2.18M -3.78200M -3.77200M 9.41M 0.33M
Begin period cash flow 2.31M 6.11M 9.88M 0.48M 0.15M
End period cash flow 4.49M 2.33M 6.11M 9.88M 0.48M
Total cash from operating activities -6.55800M -3.72900M -3.76900M -3.50100M -3.89909M
Issuance of capital stock 8.73M 0.00000M 0.00000M 13.01M 4.17M
Depreciation 0.01M 0.02M 0.04M 0.05M 0.05M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - 0.30M 0.29M -0.08500M 0.00095M
Change to account receivables - 0.00000M 0.07M 0.01000M -0.04404M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.00873M 0.00100M -0.00100M 0.01M 0.03M
Change to netincome - 0.50M 0.31M 0.18M 0.52M
Capital expenditures 0.00000M 0.00100M 0.00500M 0.05M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.19M 0.18M -0.05300M -1.03400M -0.95347M
Stock based compensation 0.28M 0.44M 0.22M 0.02M 0.51M
Other non cash items 0.20M 0.06M 0.04M 0.16M 0.00755M
Free cash flow -6.55800M -3.73000M -3.77400M -3.55400M -3.92252M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
GCTK
GlucoTrack Inc		 0.0055 3.74% 0.15 - - - 3.52 -0.9793
ISRG
Intuitive Surgical Inc		 -1.72 0.38% 455.91 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 0.36 0.28% 129.52 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 -6.29 2.43% 252.55 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 -5.86 2.92% 194.97 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

GlucoTrack Inc

301 Route 17 North, Rutherford, NJ, United States, 07070

Key Executives

Name Title Year Born
Mr. Erez Ben-Zvi GM & VP of Product 1978
Mr. Paul V. Goode Ph.D. Pres & COO 1968
Ms. Jolie G. Kahn CPA, Esq. Chief Financial Officer 1965
Mr. Avner Gal MBA, MSc.EE Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board 1954
Mr. David Malka BA Co-Founder 1965
Mr. James P. Thrower Ph.D. CTO & VP of Engineering NA
Mr. Paul V. Goode Ph.D. Chief Executive Officer 1969
Mr. Mark Tapsak Ph.D. Vice President of Technology 1969
Ms. Drinda Benjamin Vice President of Marketing 1976
Mr. James P. Thrower Ph.D. Vice President of Engineering 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.